In vitro inhibition of monkeypox virus production and spread by Interferon-β

Virology Journal

Volumn 9, Issue , 2012, Pages

  Johnston, Sara C ^a   Lin, Kenny L ^a   Connor, John H ^b   Ruthel, Gordon ^a   Goff, Arthur ^a   Hensley, Lisa E ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IFN ; Monkeypox virus; MxA; Orthopoxvirus; Type I interferon

Indexed keywords

BETA INTERFERON; MYXOVIRUS RESISTANCE PROTEIN A; ANTIVIRUS AGENT; BIOLOGICAL PRODUCT; GUANINE NUCLEOTIDE BINDING PROTEIN; MYXOVIRUS RESISTANCE PROTEINS;

ARTICLE; CONGO; HUMAN; HUMAN CELL; MONKEYPOX; MONKEYPOX VIRUS; PROTEIN EXPRESSION; VIRUS INHIBITION; BIOSYNTHESIS; CELL LINE; DRUG EFFECT; GENE EXPRESSION PROFILING; GROWTH, DEVELOPMENT AND AGING; TIME; VIRUS CULTURE; VIRUS LOAD; VIRUS REPLICATION;

COWPOX VIRUS; MONKEYPOX VIRUS; ORTHOPOXVIRUS; VACCINIA VIRUS; VARIOLA VIRUS;

ANTIVIRAL AGENTS; BIOLOGICAL AGENTS; CELL LINE; GENE EXPRESSION PROFILING; GTP-BINDING PROTEINS; HUMANS; INTERFERON-BETA; MONKEYPOX VIRUS; TIME FACTORS; VIRAL LOAD; VIRAL PLAQUE ASSAY; VIRUS CULTIVATION; VIRUS REPLICATION;

EID: 84855443562     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-5     Document Type: Article

References (69)

1. Poxviridae: the viruses and their replication. Moss B, Field's Virology Philadelphia: Lippincott-Raven, Knipe DM, Howley PM, 4 2001 2 2849 2883 22232768
2. How vaccinia virus has evolved to subvert the host immune response. Bahar MW, Graham SC, Chen RA, Cooray S, Smith GL, Stuart DI, Grimes JM, J Struct Biol 2011 175 127 134 10.1016/j.jsb.2011.03.010 21419849
3. Poxvirus genomes: a phylogenetic analysis. Gubser C, Hue S, Kellam P, Smith GL, J Gen Virol 2004 85 105 117 10.1099/vir.0.19565-0 14718625 (Pubitemid 38128875)
4. Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus. Jackson SS, Ilyinskii P, Philippon V, Gritz L, Yafal AG, Zinnack K, Beaudry KR, Manson KH, Lifton MA, Kuroda MJ, et al. J Virol 2005 79 6554 6559 10.1128/JVI.79.10.6554-6559.2005 15858042 (Pubitemid 40617262)
5. Health Workers Union Wary of Smallpox Vaccinations. Altman LK, The New York Times 2002
6. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton M, McDade J, Osterholm MT, et al. JAMA 1999 281 2127 2137 10.1001/jama.281.22.2127 10367824 (Pubitemid 29264692)
7. Clinical characteristics of human monkeypox, and risk factors for severe disease. Huhn GD, Bauer AM, Yorita K, Graham MB, Sejvar J, Likos A, Damon IK, Reynolds MG, Kuehnert MJ, Clin Infect Dis 2005 41 1742 1751 10.1086/498115 16288398 (Pubitemid 41759858)
8. Human monkeypox: clinical features of 282 patients. Jezek Z, Szczeniowski M, Paluku KM, Mutombo M, J Infect Dis 1987 156 293 298 10.1093/infdis/156.2.293 3036967 (Pubitemid 17098192)
9. Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. Meyer H, Perrichot M, Stemmler M, Emmerich P, Schmitz H, Varaine F, Shungu R, Tshioko F, Formenty P, J Clin Microbiol 2002 40 2919 2921 10.1128/JCM.40.8.2919-2921.2002 12149352 (Pubitemid 35284963)
10. Clinical manifestations of human monkeypox influenced by route of infection. Reynolds MG, Yorita KL, Kuehnert MJ, Davidson WB, Huhn GD, Holman RC, Damon IK, J Infect Dis 2006 194 773 780 10.1086/505880 16941343 (Pubitemid 44344124)
11. Monkeypox virus and insights into its immunomodulatory proteins. Weaver JR, Isaacs SN, Immunol Rev 2008 225 96 113 10.1111/j.1600-065X.2008.00691.x 18837778
12. Isolation of monkeypox virus from wild squirrel infected in nature. Khodakevich L, Jezek Z, Kinzanzka K, Lancet 1986 1 98 99 2867342 (Pubitemid 16182918)
13. The role of squirrels in sustaining monkeypox virus transmission. Khodakevich L, Szczeniowski M, Manbu ma D, Jezek Z, Marennikova S, Nakano J, Messinger D, Trop Geogr Med 1987 39 115 122 2820094 (Pubitemid 17133733)
14. Monkeypox virus in relation to the ecological features surrounding human settlements in Bumba zone, Zaire. Khodakevich L, Szczeniowski M, Nambu ma D, Jezek Z, Marennikova S, Nakano J, Meier F, Trop Geogr Med 1987 39 56 63 3037740 (Pubitemid 17075064)
15. Outbreak of human monkeypox, Democratic Republic of Congo, 1996-1997. Hutin YJ, Williams RJ, Malfait P, Pebody R, Loparev VN, Ropp SL, Rodriguez M, Knight JC, Tshioko FK, Khan AS, et al. Emerg Infect Dis 2001 7 434 438 11384521
16. Human monkeypox: disease pattern, incidence and attack rates in a rural area of northern Zaire. Jezek Z, Grab B, Paluku KM, Szczeniowski MV, Trop Geogr Med 1988 40 73 83 2841783
17. Clinico-epidemiological features of monkeypox patients with an animal or human source of infection. Jezek Z, Grab B, Szczeniowski M, Paluku KM, Mutombo M, Bull World Health Organ 1988 66 459 464 2844428
18. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, Blumberg S, Thomassen HA, Pike BL, Fair JN, et al. Proc Natl Acad Sci USA 2010 107 16262 16267 10.1073/pnas.1005769107 20805472
19. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Chen N, Li G, Liszewski MK, Atkinson JP, Jahrling PB, Feng Z, Schriewer J, Buck C, Wang C, Lefkowitz EJ, et al. Virology 2005 340 46 63 10.1016/j.virol.2005.05.030 16023693 (Pubitemid 41191177)
20. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Ladnyj ID, Ziegler P, Kima E, Bull World Health Organ 1972 46 593 597 4340218
21. The detection of monkeypox in humans in the Western Hemisphere. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, Kazmierczak JJ, Stratman EJ, Li Y, Fairley JA, et al. N Engl J Med 2004 350 342 350 10.1056/NEJMoa032299 14736926 (Pubitemid 38101629)
22. Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Learned LA, Reynolds MG, Wassa DW, Li Y, Olson VA, Karem K, Stempora LL, Braden ZH, Kline R, Likos A, et al. Am J Trop Med Hyg 2005 73 428 434 16103616 (Pubitemid 41278724)
23. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Biron CA, Semin Immunol 1998 10 383 390 10.1006/smim.1998.0138 9799713 (Pubitemid 28499552)
24. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. Randall RE, Goodbourn S, J Gen Virol 2008 89 1 47 10.1099/vir.0.83391-0 18089727
25. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Samuel CE, Virology 1991 183 1 11 10.1016/0042-6822(91)90112-O 1711253
26. The interferon system and vaccinia virus evasion mechanisms. Perdiguero B, Esteban M, J Interferon Cytokine Res 2009 29 581 598 10.1089/jir.2009.0073 19708815
27. Proteomic screening of variola virus reveals a unique NF-kappaB inhibitor that is highly conserved among pathogenic orthopoxviruses. Mohamed MR, Rahman MM, Lanchbury JS, Shattuck D, Neff C, Dufford M, van Buuren N, Fagan K, Barry M, Smith S, et al. Proc Natl Acad Sci USA 2009 106 9045 9050 10.1073/pnas. 0900452106 19451633
28. Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA. Chang HW, Jacobs BL, Virology 1993 194 537 547 10.1006/viro.1993.1292 8099244
29. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Chang HW, Watson JC, Jacobs BL, Proc Natl Acad Sci USA 1992 89 4825 4829 10.1073/pnas.89.11.4825 1350676
30. A role for Z-DNA binding in vaccinia virus pathogenesis. Kim YG, Muralinath M, Brandt T, Pearcy M, Hauns K, Lowenhaupt K, Jacobs BL, Rich A, Proc Natl Acad Sci USA 2003 100 6974 6979 10.1073/pnas.0431131100 12777633 (Pubitemid 36706378)
31. Evidence that vaccinia virulence factor E3L binds to Z-DNA in vivo: Implications for development of a therapy for poxvirus infection. Kim YG, Lowenhaupt K, Oh DB, Kim KK, Rich A, Proc Natl Acad Sci USA 2004 101 1514 1518 10.1073/pnas.0308260100 14757814 (Pubitemid 38234186)
32. Both carboxy - and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. Brandt TA, Jacobs BL, J Virol 2001 75 850 856 10.1128/JVI.75.2.850-856.2001 11134298 (Pubitemid 32037287)
33. Recombinant vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent, initiation factor 2 alpha-specific protein kinase. Carroll K, Elroy-Stein O, Moss B, Jagus R, J Biol Chem 1993 268 12837 12842 8099586 (Pubitemid 23182454)
34. The vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2. Davies MV, Elroy-Stein O, Jagus R, Moss B, Kaufman RJ, J Virol 1992 66 1943 1950 1347793
35. Homologous regions of the alpha subunit of eukaryotic translational initiation factor 2 (eIF2alpha) and the vaccinia virus K3L gene product interact with the same domain within the dsRNA-activated protein kinase (PKR). Sharp TV, Witzel JE, Jagus R, Eur J Biochem 1997 250 85 91 10.1111/j.1432-1033.1997. 00085.x 9431994 (Pubitemid 27504586)
36. The role of the PKR-inhibitory genes, E3L and K3L, in determining vaccinia virus host range. Langland JO, Jacobs BL, Virology 2002 299 133 141 10.1006/viro.2002.1479 12167348 (Pubitemid 35007518)
37. Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons. Meng X, Jiang C, Arsenio J, Dick K, Cao J, Xiang Y, J Virol 2009 83 10627 10636 10.1128/JVI.01260-09 19656868
38. Detection of a protein encoded by the vaccinia virus C7L open reading frame and study of its effect on virus multiplication in different cell lines. Oguiura N, Spehner D, Drillien R, J Gen Virol 1993 74 Pt 7 1409 1413 8336123 (Pubitemid 23230260)
39. Vaccinia virus host range genes. Perkus ME, Goebel SJ, Davis SW, Johnson GP, Limbach K, Norton EK, Paoletti E, Virology 1990 179 276 286 10.1016/0042-6822(90)90296-4 2171207 (Pubitemid 20354338)
40. The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation. Shisler JL, Jin XL, J Virol 2004 78 3553 3560 10.1128/JVI.78.7.3553-3560.2004 15016878 (Pubitemid 38568297)
41. Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2alpha. Backes S, Sperling KM, Zwilling J, Gasteiger G, Ludwig H, Kremmer E, Schwantes A, Staib C, Sutter G, J Gen Virol 2010 91 470 482 10.1099/vir.0.015347-0 19846675
42. The highly virulent variola and monkeypox viruses express secreted inhibitors of type I interferon. Fernandez de Marco Mdel M, Alejo A, Hudson P, Damon IK, Alcami A, FASEB J 2010 24 1479 1488 10.1096/fj.09-144733 20019241
43. Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy. Day SL, Ramshaw IA, Ramsay AJ, Ranasinghe C, J Immunol 2008 180 7158 7166 18490714
44. Prevention of vaccinia lesions in Rhesus monkeys by human leucocyte and fibroblast interferon. Weimar W, Stitz L, Billiau A, Cantell K, Schellekens H, J Gen Virol 1980 48 25 30 10.1099/0022-1317-48-1-25 6155433 (Pubitemid 10003057)
45. Dynamin-like MxA GTPase: structural insights into oligomerization and implications for antiviral activity. Haller O, Gao S, von der Malsburg A, Daumke O, Kochs G, J Biol Chem 2010 285 28419 28424 10.1074/jbc.R110.145839 20538602
46. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. Haller O, Kochs G, J Interferon Cytokine Res 2010 31 79 87 21166595
47. The Mx GTPase family of interferon-induced antiviral proteins. Haller O, Stertz S, Kochs G, Microbes Infect 2007 9 1636 1643 10.1016/j.micinf.2007.09.010 18062906 (Pubitemid 350217083)
48. The interferon response circuit in antiviral host defense. Haller O, Weber F, Verh K Acad Geneeskd Belg 2009 71 73 86 19739399
49. Inhibition of a large double-stranded DNA virus by MxA protein. Netherton CL, Simpson J, Haller O, Wileman TE, Takamatsu HH, Monaghan P, Taylor G, J Virol 2009 83 2310 2320 10.1128/JVI.00781-08 19109387
50. Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. Pavlovic J, Zurcher T, Haller O, Staeheli P, J Virol 1990 64 3370 3375 2161946 (Pubitemid 20219541)
51. Interferon-regulated influenza virus resistance gene Mx is localized on mouse chromosome 16. Staeheli P, Pravtcheva D, Lundin LG, Acklin M, Ruddle F, Lindenmann J, Haller O, J Virol 1986 58 967 969 2422403 (Pubitemid 16082789)
52. Interferon-induced, antiviral human MxA protein localizes to a distinct subcompartment of the smooth endoplasmic reticulum. Stertz S, Reichelt M, Krijnse-Locker J, Mackenzie J, Simpson JC, Haller O, Kochs G, J Interferon Cytokine Res 2006 26 650 660 10.1089/jir.2006.26.650 16978069 (Pubitemid 44689654)
53. Human MxA protein inhibits tick-borne Thogoto virus but not Dhori virus. Frese M, Kochs G, Meier-Dieter U, Siebler J, Haller O, J Virol 1995 69 3904 3909 7745744
54. Mechanism of human MxA protein action: variants with changed antiviral properties. Zurcher T, Pavlovic J, Staeheli P, EMBO J 1992 11 1657 1661 1314172
55. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Huggins J, Goff A, Hensley L, Mucker E, Shamblin J, Wlazlowski C, Johnson W, Chapman J, Larsen T, Twenhafel N, et al. Antimicrob Agents Chemother 2009 53 2620 2625 10.1128/AAC.00021-09 19349521
56. Smallpox vaccines for biodefense. Kennedy RB, Ovsyannikova I, Poland GA, Vaccine 2009 27 Suppl 4 73 79 19837292
57. An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies. Wiser I, Balicer RD, Cohen D, Vaccine 2007 25 976 984 10.1016/j.vaccine.2006.09.046 17074424 (Pubitemid 44937441)
58. Smallpox vaccination: a national survey of emergency health care providers. Everett WW, Coffin SE, Zaoutis T, Halpern SD, Strom BL, Acad Emerg Med 2003 10 606 611 12782520 (Pubitemid 36667063)
59. When parents say no to child vaccinations. McNeil D, The New York Times 2002
60. Update on new antivirals under development for the treatment of double-stranded DNA virus infections. Dropulic LK, Cohen JI, Clin Pharmacol Ther 2010 88 610 619 10.1038/clpt.2010.178 20881959
61. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Baker RO, Bray M, Huggins JW, Antiviral Res 2003 57 13 23 10.1016/S0166-3542(02)00196-1 12615299 (Pubitemid 36254717)
62. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Smee DF, Bailey KW, Wong MH, Sidwell RW, Antiviral Res 2001 52 55 62 10.1016/S0166-3542(01)00159-0 11530188 (Pubitemid 32800691)
63. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, Holy A, De Clercq E, Niesters HG, Fries E, Maas C, et al. Nature 2006 439 745 748 10.1038/nature04295 16341204 (Pubitemid 43237623)
64. Countermeasures to the bioterrorist threat of smallpox. Jahrling PB, Fritz EA, Hensley LE, Curr Mol Med 2005 5 817 826 10.2174/156652405774962326 16375715 (Pubitemid 43009520)
65. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm A, Chahroudi A, Chavan R, Feinberg MB, Veach D, et al. Nat Med 2005 11 731 739 10.1038/nm1265 15980865 (Pubitemid 41021205)
66. Tecovirimat for smallpox infections. Bolken TC, Hruby DE, Drugs Today (Barc) 2010 46 109 117 10.1358/dot.2010.46.2.1437244
67. A novel respiratory model of infection with monkeypox virus in cynomolgus macaques. Goff AJ, Chapman J, Foster C, Wlazlowski C, Shamblin J, Lin K, Kreiselmeier N, Mucker E, Paragas J, Lawler J, Hensley L, J Virol 2011 85 4898 4909 10.1128/JVI.02525-10 21389129
68. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM, Mucker E, Shamblin J, Bolken TC, Wlazlowski C, et al. Antimicrob Agents Chemother 2009 53 1817 1822 10.1128/AAC.01596-08 19223621
69. Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein-B5R membrane protein chimera. Ward BM, Moss B, J Virol 2001 75 4802 4813 10.1128/JVI.75.10.4802-4813.2001 11312352 (Pubitemid 32381523)